Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cumulative incidences of MR4

Published byLaureen Mathews Modified over 5 years ago

Similar presentations

Presentation on theme: "Cumulative incidences of MR4"— Presentation transcript:

1 Cumulative incidences of MR4
Cumulative incidences of MR4.0 according to KIR haplotypes and activating and inhibitory KIRs. A, Cumulative incidences of MR4.0 (%MR4.0) over time are presented according to different KIR haplotypes. Cumulative incidences of MR4.0 according to KIR haplotypes and activating and inhibitory KIRs. A, Cumulative incidences of MR4.0 (%MR4.0) over time are presented according to different KIR haplotypes. Solid line, patients homozygous for KIR haplotype A (A/A); dashed line, B/x haplotypes (A/B and B/B; P = 0.214). B, %MR4.0 are presented according to the presence or absence of functional combinations of activating KIR and HLA genes. Solid line, patients with activating KIRs and their ligands; dashed line, patients without those combinations (P = 0.918). C and D, %MR4.0 are presented according to the number of combinations of inhibitory KIRs and their ligands. C, Black solid line, patients without any combinations; black dashed line, one combination; gray solid line, two combinations; gray dashed line, three combinations (P = 0.368). D, Patients were divided into highly licensed (number of combinations of inhibitory KIRs and their ligands: two or three) and poorly licensed (zero or one). Solid line, highly licensed patients; dashed line, poorly licensed patients (P = 0.818). All curve comparisons were completed using log-rank tests for time to achievement of MR4.0, and P < 0.05 were considered statistically significant. Number of patient indicted in A–D. Hiroshi Ureshino et al. Cancer Immunol Res 2018;6: ©2018 by American Association for Cancer Research

Download ppt "Cumulative incidences of MR4"

Similar presentations

Supplementary Table 1 Table S1. Population frequency of HLA -A, -B and -C alleles. Rare alleles (frequency < 0.5%) are highlighted by a grey background.

Supplementary Table 1 Table S1. Population frequency of HLA -A, -B and -C alleles. Rare alleles (frequency < 0.5%) are highlighted by a grey background.
Haploidentical hematopoietic transplantation from KIR ligand–mismatched donors with activating KIRs reduces nonrelapse mortality by Antonella Mancusi,

Haploidentical hematopoietic transplantation from KIR ligand–mismatched donors with activating KIRs reduces nonrelapse mortality by Antonella Mancusi,
Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.

Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.
Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.
Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT.

Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.
Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.
Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.

Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.
PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.
The absence of ADCC by nivolumab in vitro.

The absence of ADCC by nivolumab in vitro.
Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.
Donor Killer Immunoglobulin-Like Receptor (KIR) Genotype-Patient Cognate KIR Ligand Combination and Antithymocyte Globulin Preadministration Are Critical.

Donor Killer Immunoglobulin-Like Receptor (KIR) Genotype-Patient Cognate KIR Ligand Combination and Antithymocyte Globulin Preadministration Are Critical.
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Statistical Considerations in Studies of Late Effects in HCT

Statistical Considerations in Studies of Late Effects in HCT
Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.
Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical.

Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical.
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Kaplan–Meier curves for the time until development of microscopic polyangiitis (MPA) (A) and for survival (B) in myeroperoxidase-antineutrophil cytoplasmic.

Kaplan–Meier curves for the time until development of microscopic polyangiitis (MPA) (A) and for survival (B) in myeroperoxidase-antineutrophil cytoplasmic.

Similar presentations

Ads by Google